|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AA37
|
|
gptkbp:CASNumber
|
1187594-09-7
|
|
gptkbp:chemicalFormula
|
C16H17N7O2S
|
|
gptkbp:contraindication
|
severe hepatic impairment
active tuberculosis
|
|
gptkbp:drugClass
|
Janus kinase inhibitor
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
1 mg
2 mg
4 mg
|
|
gptkbp:genericName
|
gptkb:baricitinib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Olumiant
|
|
gptkbp:indication
|
COVID-19 in hospitalized adults
moderate to severe rheumatoid arthritis
severe alopecia areata
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanismOfAction
|
JAK1 and JAK2 inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D
N
not recommended
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
shingles
herpes simplex
increased cholesterol
upper respiratory tract infection
|
|
gptkbp:usedFor
|
gptkb:COVID-19
rheumatoid arthritis
alopecia areata
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly
|
|
gptkbp:bfsLayer
|
6
|